Alterations of Gut Microbiota and the Brain-Immune-Intestine Axis in Patients With Relapsing-Remitting Multiple Sclerosis After Treatment With Oral Cladribine: Protocol for a Prospective Observational Study
BackgroundImmunological factors are the key to the pathogenesis of multiple sclerosis (MS). Conjointly, environmental factors are known to affect MS disease onset and progression. Several studies have found that the intestinal microbiota in MS patients differs from that of co...
Main Authors: | van Pamelen, Jeske, van Olst, Lynn, Budding, Andries E, de Vries, Helga E, Visser, Leo H |
---|---|
Format: | Article |
Language: | English |
Published: |
JMIR Publications
2020-07-01
|
Series: | JMIR Research Protocols |
Online Access: | http://www.researchprotocols.org/2020/7/e16162/ |
Similar Items
-
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
by: Budhia, S., et al.
Published: (2019) -
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
by: Julie A Murphy, et al.
Published: (2010-09-01) -
Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
by: Mohamed AlJumah, et al.
Published: (2020-02-01) -
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
by: Giancarlo Comi, et al.
Published: (2018-01-01) -
Work Participation and Executive Abilities in Patients with Relapsing-Remitting Multiple Sclerosis.
by: Karin van der Hiele, et al.
Published: (2015-01-01)